Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of Finnzymes. The business is a well-recognized provider of integrated tools for high-performance polymerase chain reaction (PCR), including reagents, instruments, consumables and kits that make the PCR process faster and more accurate for applications including basic genomic research, genetic testing, forensics and food safety.
Finnzymes, which generated full year 2009 revenues of $20 million, will be integrated primarily into Thermo Fisher’s Analytical Technologies Segment, with certain equipment and consumables product lines being added to the Laboratory Products and Services Segment.
Thermo Fisher Scientific acknowledges the winners of 2020 TMT Research Grant Award